Anilkumar G. Nair
Anilkumar G. Nair has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Joseph A. Kozlowski
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
4 shared publicationsQingbei Zeng
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
4 shared publicationsStuart B. Rosenblum
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
4 shared publicationsYueheng Jiang
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
4 shared publicationsNeng-Yang Shih
Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
3 shared publicationsOleg Selyutin
Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
3 shared publications
Latest Publications
- 28 January 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 336-343
Heterocyclic Assembly: An Underutilized Disconnection with Potential to Maximize High Fsp3 Chemical Space Exploration
From a retrosynthetic standpoint, functionalization or synthesis of heterocyclic cores are fundamental disconnections that chemists make. This manuscript highlights heterocycle synthesis as the strategic bond disconnection by leveraging ubiquitous building blocks, carboxylic acids and amines, for preparation of heterocyclic cores in a library-friendly format. This heterocyclic formation strategy allows medicinal chemists to access much wider chemical space, especially for analogs with higher Fsp3 vs state-of-the-art heterocycle functionalization methods. The direct impact on medicinal chemistry programs is underscored by adapting and miniaturizing the synthesis of N2-indazoles and C2-benzimidazoles to μ-scale parallel medicinal chemistry (PMC) libraries, affording a similar success rate (80%) as venerable Suzuki and Buchwald-Hartwig libraries.
- 28 January 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 336-343
Heterocyclic Assembly: An Underutilized Disconnection with Potential to Maximize High Fsp3 Chemical Space Exploration
From a retrosynthetic standpoint, functionalization or synthesis of heterocyclic cores are fundamental disconnections that chemists make. This manuscript highlights heterocycle synthesis as the strategic bond disconnection by leveraging ubiquitous building blocks, carboxylic acids and amines, for preparation of heterocyclic cores in a library-friendly format. This heterocyclic formation strategy allows medicinal chemists to access much wider chemical space, especially for analogs with higher Fsp3 vs state-of-the-art heterocycle functionalization methods. The direct impact on medicinal chemistry programs is underscored by adapting and miniaturizing the synthesis of N2-indazoles and C2-benzimidazoles to μ-scale parallel medicinal chemistry (PMC) libraries, affording a similar success rate (80%) as venerable Suzuki and Buchwald-Hartwig libraries.
- Top Cited PapersOpen Access
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 144-158
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 144-158
Top Cited PapersOpen AccessOrally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1954-1957
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1954-1957
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
- 1 February 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (4) , 1085-1088
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: Improved PK, hERG and metabolic profiles
- 1 February 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (4) , 1085-1088
IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: Improved PK, hERG and metabolic profiles
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (1) , 713-717
II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides
- 1 January 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (1) , 713-717
II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides
- 1 September 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (18) , 5336-5341
I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles
- 1 September 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (18) , 5336-5341
I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles